top of page
Search

Can wearables really catch silent atrial fibrillation—and what can’t they do (yet)?

Summary: 

New randomized trials and reviews show that patches and smart devices can detect more previously-unknown atrial fibrillation (AF) than usual care, but proving stroke reduction is still a work-in-progress. Wearables are most useful for higher-risk adults and symptom-curious patients when data are interpreted and confirmed with medical-grade ECG. At Zelica Health, we offer a clinic-supervised screening pathway and help you pick the right device—then we interpret the signal, not the noise. JAMA Network+2Oxford Academic+2


What’s new & why it matters: 

In a randomized trial, smartphone screening more than doubled the detection of treatment-relevant silent Atrial Fibrillation (AF) vs usual care; a large home-patch trial also found ~4× more AF at 4 months (3.9% vs 0.9%). Detecting AF early matters because anticoagulation can prevent stroke—but trials haven’t yet nailed down stroke reduction from screening itself. Oxford Academic+2JAMA Network+2

👉 Book a preventive consult—same-day telehealth available.


Photo showing a stylised smartwatch ECG and AF patch with bullets: “Detect abnormal heart rhythm” but ECG confirmation still needed.
Smartwatch + patch: great for flagging possible AF—but decisions still rely on ECG confirmation and clinical review.

Who this is for

  • Adults 50+ with cardiovascular risk factors (e.g., hypertension, diabetes, sleep apnoea, obesity).

  • Anyone with palpitations, unexplained fatigue, breathlessness, or smartwatch “irregular rhythm” alerts.

  • People with family history of AF or prior stroke/TIA (without known AF).

  • Post-COVID or endurance athletes noticing erratic heart-rate trends.

  • Anyone who wants clinician-supervised device choice + medical-grade confirmation before making big decisions.


What the latest research shows about silent Atrial Fibrillation (AF)

  • Wearables & apps can find more AF.

    • mSToPS: A self-applied ECG patch (up to 4 weeks) detected 3.9% vs 0.9% new AF at 4 months vs delayed monitoring. JAMA Network

    • eBRAVE-AF: Smartphone PPG more than doubled detection of treatment-relevant AF vs usual care. Oxford Academic

  • Outcomes are mixed (so far).

    • LOOP (implantable recorder): more AF found and more anticoagulation started, no significant stroke reduction vs usual care. The Lancet

    • STROKESTOP (handheld ECG in 75–76-year-olds): showed a small clinical benefit on a composite outcome over ~6.9 years. The Lancet

  • Accuracy is promising, not perfect.

    • Apple Heart Study: among those notified, the PPV was 0.84 for AF on confirmatory ECG—great, but not a diagnosis by itself. New England Journal of Medicine

  • Guidelines keep us sensible.

    • USPSTF: evidence insufficient to recommend routine AF screening in asymptomatic adults. USPSTF

    • ESC 2024: supports opportunistic screening and using digital tools in the right patients, with ECG confirmation and risk-factor care. Oxford Academic

Bottom line: Wearables are great at raising the flag; your clinic confirms, stratifies stroke risk, and makes the treatment call.

Inline CTA: Book a preventive consult—same-day telehealth available.👉 Book now


What to do next (your step-by-step)

  1. Risk snapshot (10 minutes). Book a quick telehealth consult. We’ll check CHA₂DS₂-VASc risk, medications, sleep, and triggers.

  2. Pick the right device (not one-size-fits-all).

    • Symptom-curious or watch owner? We’ll configure your alerts and teach when to record (watch ECG or Kardia).

    • Higher-risk or frequent symptoms? We’ll organise medical-grade monitoring (24-hour Holter or multi-day patch) to confirm AF episodes.

  3. Confirm with ECG. Any wearable alert gets ECG confirmation (12-lead or rhythm strip) before treatment decisions. Oxford Academic

  4. Decide smartly. If AF is confirmed, we’ll discuss stroke prevention (anticoagulation), blood-pressure/sleep optimisation, and lifestyle levers.

  5. Close the loop. You’ll get a written plan, device settings that actually help, and follow-ups (one-off or via our subscription care).


Costs & access in Australia (what to expect)

  • Medical-grade tests (Medicare-eligible):

    • 12-lead ECG: MBS Category 2 items include 11707/11714 (clinician-performed/ reported ECG). Rebates apply; exact out-of-pocket depends on your provider’s fees. Health Australia

    • Ambulatory ECG (Holter/patch): MBS 11716 (≥12-hour continuous recording, by request/referral) is available; laboratories differ in billing policies. Health Australia

    • Many pathology providers bulk bill eligible patients for Holter/ECG; some charge a small fitting fee (e.g., AU$25) and return reports in ~5 business days. Check locally. clinpath.com.au+1

  • Consumer devices (buy-once hardware):

    • Apple Watch Series 9 (ECG on supported models): from ~AU$649 RRP in Australia (prices vary by model/retailer). TechRadar

    • Withings ScanWatch (ECG-capable models) commonly retail ~AU$799 at AU retailers. EFTM

    • KardiaMobile single/6-lead pocket ECG: typically ~AU$180–$250 depending on model and seller. Best Deals AU

Good to know: Device notifications are not diagnoses. We’ll help you confirm AF, interpret data, and avoid false alarms before any treatment. New England Journal of Medicine

👉High-risk or symptom-curious? We’ll pick the right device and interpret the data for you.


FAQs

1) If my watch says “irregular rhythm,” do I have AF?

Not necessarily. Wearables flag suspicion; AF is confirmed by ECG. We’ll review the tracing and arrange 12-lead ECG/Holter if needed. New England Journal of Medicine+1


2) Do wearables reduce stroke?

They detect more AF. A large implantable-monitor trial (LOOP) did not show stroke reduction vs usual care; one population handheld trial (STROKESTOP) suggested small benefit on a composite outcome. More outcome-driven RCTs are ongoing. The Lancet+1


3) Are guidelines for or against screening everyone?

The USPSTF says evidence is insufficient for routine screening in asymptomatic adults; ESC 2024 supports opportunistic checks and digital tools with ECG confirmation in the right patients. USPSTF+1


4) Which device is “best”?

It depends: PPG smartwatches are great for passive alerts; ECG-capable watches and KardiaMobile capture on-demand ECGs; patch/Holter shows the whole story over days. We tailor to your symptoms and risk. JAMA Network


5) How long will I wait for results?

Consumer ECGs are instant; Holter/patch reports are usually back in ~5 business days at Australian labs—we’ll fast-track interpretation for you. Clinical Labs



Internal links


Futuristic looking heart monitor device, meaning the future of wearable medical tech is close, but expert opinion still required for correct diagnosis.
The future of wearable medical tech is close, but expert opinion still required for correct diagnosis. Learn more at Zelica.

References

  1. Steinhubl SR, et al. mSToPS randomized trial (JAMA 2018): higher AF detection with self-applied patch vs delayed monitoring. JAMA Network

  2. eBRAVE-AF randomized trial: digital smartphone screening doubled treatment-relevant AF detection vs usual care. Oxford Academic

  3. LOOP Trial (Lancet): more AF detected, no significant stroke reduction vs usual care. The Lancet

  4. STROKESTOP Trial (Lancet): small clinical benefit of population screening in older adults. The Lancet

  5. Apple Heart Study (NEJM): PPV 0.84 for AF among those notified. New England Journal of Medicine

  6. USPSTF 2022: insufficient evidence to recommend routine AF screening in asymptomatic adults. USPSTF

  7. ESC 2024 AF Guidelines: endorse opportunistic screening & ECG confirmation. Oxford Academic

  8. MBS (Australia): 11707/11714 (12-lead ECG) and 11716 (≥12-hr ambulatory ECG) descriptors & eligibility. Health Australia+1

  9. AU lab example: Holter fitting fee & typical report turnaround. clinpath.com.au+1

  10. Indicative AU retail pricing: Apple Watch (Series 9), Withings ScanWatch, KardiaMobile. TechRadar+2EFTM+2

Comments

Rated 0 out of 5 stars.
No ratings yet
Add a rating
bottom of page